I-BET151 selectively regulates IL-6 production

Area of Science:

• Immunology
• Epigenetics
• Pharmacology

Background:

• Inflammatory response orchestration is vital for pathogen clearance.
• Cytokine production is generally thought to be regulated by common mechanisms.
• Emerging evidence suggests differential epigenetic regulation of cytokine expression.

Purpose of the Study:

• To investigate the effect of BET bromodomain protein (BRD) inhibitor I-BET151 on cytokine production.
• To elucidate the epigenetic mechanisms underlying IL-6 regulation.
• To evaluate the therapeutic potential of I-BET151 in an experimental autoimmune encephalomyelitis mouse model.

Main Methods:

• Treatment of RAW264.7 cells with lipopolysaccharide (LPS) and I-BET151.
• Measurement of cytokine production (IL-6, TNFα, IL-1β, IL-10).
• Analysis of CBP binding to the IL-6 promoter and p65-NF-κB activity.
• In vivo studies using the experimental autoimmune encephalomyelitis mouse model.

Main Results:

• I-BET151 selectively inhibited IL-6 production in LPS-stimulated cells.
• Other cytokines (TNFα, IL-1β, IL-10) were not significantly affected by I-BET151 at the tested concentration.
• I-BET151 prevented CBP binding to the IL-6 promoter without altering p65-NF-κB signaling.
• I-BET151 treatment reduced early clinical symptoms in a mouse model of multiple sclerosis.

Conclusions:

• BET proteins play a selective role in regulating IL-6 production through epigenetic mechanisms.
• Targeting BET proteins with inhibitors like I-BET151 may be a viable strategy for managing inflammatory diseases.
• This approach could reduce inflammation and disease severity in conditions such as multiple sclerosis.